BR9808239A - Composição farmacêutica administrável por via oral, e, processo de preparação da mesma - Google Patents

Composição farmacêutica administrável por via oral, e, processo de preparação da mesma

Info

Publication number
BR9808239A
BR9808239A BR9808239-6A BR9808239A BR9808239A BR 9808239 A BR9808239 A BR 9808239A BR 9808239 A BR9808239 A BR 9808239A BR 9808239 A BR9808239 A BR 9808239A
Authority
BR
Brazil
Prior art keywords
matrices
composition
mixtures
hydrophilic
weight
Prior art date
Application number
BR9808239-6A
Other languages
English (en)
Inventor
Domenico Fanara
Monique Berwaer
Anne Bouquelle
Michel Deleers Belga
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of BR9808239A publication Critical patent/BR9808239A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ADMINISTRáVEL POR VIA ORAL, E, PROCESSO DE PREPARAçãO DA MESMA". A presente invenção refere-se a composições farmacêuticas administráveis por via oral, permitindo a liberação controlada de pelo menos uma substância ativa, compreendendo a) pelo menos a referida substância ativa, b) entre 5 e 60 % em peso, relativamente ao peso total da composição, de pelo menos um excipiente selecionado dentre as matrizes inertes, as matrizes hidrófilas, as misturas lipídicas, as misturas de matrizes inertes e matrizes lipídicas, as misturas de matrizes hidrófilas e matrizes inertes, com exceção das misturas que compreendem um ácido poliacrílico e pelo menos uma matriz hidrófila de tipo celulósico; c) entre 5 e 50 % em peso, relativamente ao peso total da composição, de pelo menos um agente alcalinizante solúvel numa fase aquosa em condições de pH fisiológico, selecionado dentre os hidróxidos, os carbonatos, os bicarbonatos e os fosfatos de metais alcalinos ou alcalino-terrosos, o borato de sódio, bem como os sais básicos de ácidos orgânicos. A invenção refere-se também a processos de preparação destas composições, a composições farmacêuticas de camadas múltiplas compreendendo pelo menos uma camada que possui esta composição, e a processos de preparaçãso deste tipo de composições de camadas múltiplas.
BR9808239-6A 1997-03-14 1998-03-13 Composição farmacêutica administrável por via oral, e, processo de preparação da mesma BR9808239A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700225A BE1011045A3 (fr) 1997-03-14 1997-03-14 Compositions pharmaceutiques pour la liberation controlee de substances actives.
PCT/BE1998/000033 WO1998041194A1 (fr) 1997-03-14 1998-03-13 Compositions pharmaceutiques pour la liberation controlee de substances actives

Publications (1)

Publication Number Publication Date
BR9808239A true BR9808239A (pt) 2000-05-16

Family

ID=3890403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808239-6A BR9808239A (pt) 1997-03-14 1998-03-13 Composição farmacêutica administrável por via oral, e, processo de preparação da mesma

Country Status (20)

Country Link
US (3) US6699502B1 (pt)
EP (1) EP1007005B1 (pt)
JP (1) JP2001524950A (pt)
KR (1) KR100500775B1 (pt)
CN (1) CN1126536C (pt)
AT (1) ATE275943T1 (pt)
AU (1) AU736052B2 (pt)
BE (1) BE1011045A3 (pt)
BR (1) BR9808239A (pt)
CA (1) CA2283133C (pt)
DE (1) DE69826290T2 (pt)
ES (1) ES2229483T3 (pt)
HK (1) HK1026152A1 (pt)
ID (1) ID22980A (pt)
IL (1) IL131292A (pt)
NZ (1) NZ337345A (pt)
PL (1) PL190735B1 (pt)
RO (1) RO120602B1 (pt)
RU (1) RU2179017C2 (pt)
WO (1) WO1998041194A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
JP2001107258A (ja) * 1999-10-06 2001-04-17 Hitachi Ltd 無電解銅めっき方法とめっき装置および多層配線基板
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
AU2002227383B2 (en) * 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
KR20090029314A (ko) 2001-06-28 2009-03-20 유씨비 파쉼 소시에떼아노님 세티리진 및 슈도에페드린을 포함하는 정제
RO122476B1 (ro) * 2001-06-28 2009-07-30 Ucb S.A. Tabletă conţinând cetirizină şi pseudoefedrină
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
WO2003057198A1 (fr) * 2002-01-09 2003-07-17 Ucb, S.A. Compositions pharmaceutiques a liberation modifiee
BR0308927A (pt) * 2002-04-04 2005-01-04 Pfizer Prod Inc Comprimido mastigável de sabor agradável
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060122194A1 (en) * 2002-12-06 2006-06-08 Ucb Farchim S.A. Tablet comprising efletirizine and pseudoephedrine
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
EA014961B1 (ru) * 2005-07-26 2011-04-29 Юсб Фарма С.А. Фармацевтические композиции, включающие леветирацетам, и способы их получения
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
CA2637755A1 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2029116A4 (en) * 2006-06-19 2012-07-04 Accu Break Technologies Inc SECURE PHARMACEUTICAL FORMS
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8045677B2 (en) 2006-09-25 2011-10-25 Koninklijke Philips Electronics N V Eindhoven Shifting an object for complete trajectories in rotational X-ray imaging
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US8394415B2 (en) * 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009049405A1 (en) * 2007-10-16 2009-04-23 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
JP2011504184A (ja) * 2007-11-21 2011-02-03 ザ プロクター アンド ギャンブル カンパニー 咳治療に有用な製剤、方法及びキット
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
ES2795291T3 (es) 2013-02-13 2020-11-23 Procter & Gamble Medicamento con sabor a anís
KR102070076B1 (ko) * 2013-05-03 2020-01-29 주식회사 제닉 탄산 함유 입자를 포함하는 필름
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3116500B1 (en) 2014-03-11 2023-09-13 RedHill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating diarrhea predominant irritable bowel syndrome
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
RU2687715C1 (ru) * 2018-05-07 2019-05-15 Федеральное государственное бюджетное учреждение науки Институт горного дела Дальневосточного отделения Российской академии наук Способ комбинированной разработки россыпных месторождений золота
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR102073185B1 (ko) * 2019-07-16 2020-02-04 (주)위바이오트리 활성성분을 포함하는 변성 다중층 수산화물 구조체를 포함하는 금속 수산화물 복합체 및 이의 제조 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477033A (en) * 1892-06-14 Bicycle
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3681348D1 (de) 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPS6396126A (ja) * 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5411748A (en) * 1992-10-22 1995-05-02 Song Moon K Prostate extract supplemented with zinc
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
NZ288185A (en) * 1994-06-15 1998-02-26 Dumex Alpharma As Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
AU5609998A (en) * 1997-01-10 1998-08-03 Abbott Laboratories Tablet for the controlled release of active agents
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.

Also Published As

Publication number Publication date
IL131292A0 (en) 2001-01-28
KR20000076269A (ko) 2000-12-26
DE69826290T2 (de) 2005-02-17
AU736052B2 (en) 2001-07-26
CN1126536C (zh) 2003-11-05
US7083807B2 (en) 2006-08-01
KR100500775B1 (ko) 2005-07-12
US6699502B1 (en) 2004-03-02
EP1007005B1 (fr) 2004-09-15
PL190735B1 (pl) 2005-12-30
RU2179017C2 (ru) 2002-02-10
CN1250371A (zh) 2000-04-12
US20040086563A1 (en) 2004-05-06
ATE275943T1 (de) 2004-10-15
EP1007005A1 (fr) 2000-06-14
CA2283133C (fr) 2006-07-25
IL131292A (en) 2004-07-25
US20020110596A1 (en) 2002-08-15
AU6387398A (en) 1998-10-12
RO120602B1 (ro) 2006-05-30
NZ337345A (en) 2000-04-28
JP2001524950A (ja) 2001-12-04
PL335832A1 (en) 2000-05-22
DE69826290D1 (de) 2004-10-21
ES2229483T3 (es) 2005-04-16
CA2283133A1 (fr) 1998-09-24
ID22980A (id) 1999-12-23
HK1026152A1 (en) 2000-12-08
WO1998041194A1 (fr) 1998-09-24
BE1011045A3 (fr) 1999-04-06

Similar Documents

Publication Publication Date Title
BR9808239A (pt) Composição farmacêutica administrável por via oral, e, processo de preparação da mesma
RU99119084A (ru) Фармацевтические композиции для контролируемого высвобождения активных веществ
KR101719008B1 (ko) 약물 투여용 조성물
US20050089573A1 (en) Oral pharmaceutical formulation containing ibandronate
WO2014022660A1 (en) Curcumin analogs and methods of making and using thereof
WO2005070417A1 (en) Compression coated tablet comprising sumatriptan
ES2811674B2 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
ES2201460T3 (es) Preparacion solida estable que contiene vitamina d3 y fosfato tricalcico.
US6521262B2 (en) Solid instant-release forms of administration and process for producing the same
HU228026B1 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
KR20100032893A (ko) 안정적인 ｓ-아데노실메티오닌의 염 및 이를 제조하기 위한 방법
JO2092B1 (en) Pharmaceutical compounds for restricted release of active substances
NO753674L (pt)
ES2288117A1 (es) Composicion farmaceutica solida de gabapentina.
AR012266A1 (es) Composiciones farmaceuticas para la liberacion controlada de sustancias activas y procedimiento para su preparacion.
NZ207768A (en) Sustained release tablets comprising dipyridamole
JPH0623104B2 (ja) 治療作用をもつ新規な、スルホン樹脂を含有する医薬及びその製造方法
BR0108433A (pt) sistemas flavorizantes para composições farmacêuticas e métodos para fazer tais composições
BRPI0407596A (pt) formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico
EP1818050A1 (de) Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor
TH36198A (th) สารประกอบทางเภสัชกรรมสำหรับควบคุมการปลดปล่อยสารออกฤทธิ์
CA2193838A1 (en) Disease preventive/remedy
NO841437L (no) Fremgangsmaate for fremstilling av orale doseringsformer av medisinsk aktive 1,4-dihydropyridin-derivater
JPH07215878A (ja) 骨粗そう症治療剤及び骨形成促進剤
NL8602139A (nl) Remming van parathyroide hormoonsecretie.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36 DA LPI .